Damora Therapeutics, Inc. - Ordinary Shares (DMRA)

In our clinic, the medical need for disease-modifying treatments in mutant calreticulin-driven myeloproliferative neoplasms like essential thrombocythemia and myelofibrosis is immense. Watching Damora advance their anti-mutCALR pipeline—specifically DMR-001—into clinical development in 2026 is critical to watch. From a scientific protocol standpoint, broad mutation coverage combined with optimized patient convenience could truly shift the treatment paradigm if their early-stage clinical trial endpoints pan out successfully.

On our desk, DMRA has been catching significant momentum following the corporate name change from Galecto and subsequent equity conversion approvals. Trading around $31 with a $1.9 billion market cap, the valuation heavily prices in the potential of their hematology pipeline. Wedbush maintaining an Outperform rating and raising its target to $40 provides a strong tailwind, but investors must remain cognizant that P/S multiples remain undefined due to zero trailing revenue.

Looking at the balance sheet and financial ratios, the company maintains a robust quick ratio above 22, indicating healthy short-term liquidity. However, the trailing return on equity of roughly -89.5% and anormalized ROE near -500% underscore the classic high-burn profile of a clinical-stage biotechnology firm. While the cash cushion gives them runway, the substantial share count expansion from preferred conversions means dilution risk is an ongoing structural factor to monitor closely.